Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Open-label onderzoek om de veiligheid en werkzaamheid van CABA-201 te evalueren bij proefpersonen met actieve idiopathische inflammatoire myopathie

12 november 2026 bijgewerkt door: Cabaletta Bio

Een fase 1/2, open-label onderzoek om de veiligheid en werkzaamheid van autologe CD19-specifieke chimere antigeenreceptor-T-cellen (CABA-201) te evalueren bij proefpersonen met actieve idiopathische inflammatoire myopathie

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Studietype

Ingrijpend

Inschrijving (Geschat)

74

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Göttingen, Duitsland, 37075
        • Nog niet aan het werven
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Jana Zschüntzsch
      • Roma, Italië, 00165
        • Werving
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Professor Franco Locatelli
      • London, Verenigd Koninkrijk, WC1N 3BG
        • Werving
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Verenigd Koninkrijk, SE5 9RS
        • Werving
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Verenigd Koninkrijk, WC1N 3JH
        • Werving
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Professor Despina Eleftheriou
      • Manchester, Verenigd Koninkrijk, M13 9WL
        • Werving
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Verenigd Koninkrijk, M6 8HD
        • Werving
        • Salford Royal Hospital - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
    • California
      • Orange, California, Verenigde Staten, 92868
        • Werving
        • University of California Irvine - Accepting Adult Patients
        • Hoofdonderzoeker:
          • Tahseen Mozaffar, MD
        • Contact:
      • San Francisco, California, Verenigde Staten, 94158
        • Werving
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80046
        • Werving
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Hoofdonderzoeker:
          • Dr. Kentaro Yomogida, MD
        • Contact:
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32224
        • Werving
        • Mayo Clinic Florida - Accepting Adult Patients
        • Contact:
      • St. Petersburg, Florida, Verenigde Staten, 33701
        • Werving
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Hoofdonderzoeker:
          • Natalie Booth, DO
        • Contact:
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30032
        • Werving
        • Emory University - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Verenigde Staten, 30029
        • Werving
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Hoofdonderzoeker:
          • Shanmuganathan Chandrakasan, MD
        • Contact:
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Hoofdonderzoeker:
          • Dr. George Georges, MD
        • Contact:
      • Chicago, Illinois, Verenigde Staten, 60637
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • University of Kansas Medical Center - Accepting Adult Patients
        • Contact:
    • Maryland
      • Bethesda, Maryland, Verenigde Staten, 20892
        • Werving
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Werving
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Hoofdonderzoeker:
          • Susan Prockop, MD
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48105
        • Werving
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55902
        • Werving
        • Mayo Clinic - Accepting Adult Patients
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10021
        • Werving
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • David R. Fernandez, MD, PhD
      • New York, New York, Verenigde Staten, 10021
        • Werving
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Hoofdonderzoeker:
          • Jae Park, MD
        • Contact:
      • The Bronx, New York, Verenigde Staten, 10467
        • Werving
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • Werving
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Hoofdonderzoeker:
          • Saira Sheikh, MD
        • Contact:
      • Durham, North Carolina, Verenigde Staten, 27710
        • Werving
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Hoofdonderzoeker:
          • Kaveh Ardalan, MD, MS
        • Contact:
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Werving
        • Oregon Health & Science University - Accepting Adult Patients
        • Contact:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15261
        • Werving
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Contact:
        • Hoofdonderzoeker:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15224
        • Werving
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Werving
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Contact:
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • Werving
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Hoofdonderzoeker:
          • Samuel John, MD
        • Contact:
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Houston Methodist Hospital - Accepting Adult Patients
        • Contact:
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Hoofdonderzoeker:
          • Huifang (Linda) Lu, MD
        • Contact:
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84113
        • Werving
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Verenigde Staten, 98105
        • Werving
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Contact:
        • Hoofdonderzoeker:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Nog niet aan het werven
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Hoofdonderzoeker:
          • Sara Sabbagh, DO
        • Contact:
          • Erin Hammelev - Research Coordinator
          • Telefoonnummer: 414-337-7064
          • E-mail: ehammele@mcw.edu

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar tot 75 jaar (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andere namen:
  • Resee-cel
  • Resecabtagene autoleucel
Experimenteel: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andere namen:
  • Resee-cel
  • Resecabtagene autoleucel
Experimenteel: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andere namen:
  • Resee-cel
  • Resecabtagene autoleucel

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 1/2: Incidence and severity of adverse events (AEs)
Tijdsspanne: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of adverse events and laboratory abnormalities
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Tijdsspanne: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Tijdsspanne: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie stoel: Medical Director, Cabaletta Bio

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 december 2023

Primaire voltooiing (Geschat)

1 juli 2028

Studie voltooiing (Geschat)

1 juli 2028

Studieregistratiedata

Eerst ingediend

16 november 2023

Eerst ingediend dat voldeed aan de QC-criteria

30 november 2023

Eerst geplaatst (Werkelijk)

4 december 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .